Literature DB >> 25865061

Natural History of Clinical Recurrence Patterns of Lymph Node-Positive Prostate Cancer After Radical Prostatectomy.

Marco Moschini1, Vidit Sharma1, Fabio Zattoni1, J Fernando Quevedo2, Brian J Davis3, Eugene Kwon1, R Jeffrey Karnes4.   

Abstract

BACKGROUND: Patients with lymph node (LN)-positive prostate cancer (PCa) at radical prostatectomy (RP) face a high risk of cancer recurrence. Nevertheless, recurrence patterns of LN-positive PCa and their prognostic significance remain understudied in the literature.
OBJECTIVE: To analyze a large single-institution series with long-term follow-up to elucidate the various clinical recurrence patterns of LN-positive PCa and their association with oncologic outcomes. DESIGN, SETTING, AND PARTICIPANTS: Years 1987-2012 of a prospectively maintained institutional RP registry were queried for men with LN-positive PCa at RP. Clinical recurrences were categorized as local, nodal, skeletal, or visceral. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: In addition to descriptive statistics and Kaplan-Meier analysis, univariable and multivariable Cox proportional hazards models were constructed to predict recurrence and to quantify the impact of recurrence patterns on cancer-specific mortality (CSM). RESULTS AND LIMITATIONS: Data from 1011 men with LN-positive PCa at RP were analyzed with 17.6 yr of median follow-up. The 15-yr clinical recurrence rate was 33% (95% confidence interval [CI], 31-35%) for all patients and 52.2% (95% CI, 47.3-57.1%) for patients with biochemical recurrence. The solitary locations were skeletal (n=94, 55%), nodal (n=59, 34%), local soft tissue (n=29, 17%), and visceral (n=8, 5%). Significant multivariable predictors of recurrence were Gleason score 8-10, number of positive nodes, pathologic Gleason score, and more recent year of surgery. The 15-yr CSM after clinical recurrence was 80%, with a mean overall survival of 30 mo after recurrence. On multivariable analysis, recurrences after 5 yr from RP (hazard ratio [HR]: 0.05), multiple recurrences (HR: 1.97), skeletal (HR: 3.13), and visceral metastases (HR: 7.43) were independently associated with CSM (all p<0.05).
CONCLUSIONS: Recurrences after RP for LN-positive PCa are heterogeneous in terms of time from RP, location, and number of concomitant lesions. PATIENT
SUMMARY: We found that impact of recurrence patterns on cancer-specific mortality varies significantly and allows these patients to be stratified for purposes of prognostication, follow-up, and therapy.
Copyright © 2015 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Lymph node; Metastasis; Prostate cancer; Recurrence

Mesh:

Substances:

Year:  2015        PMID: 25865061     DOI: 10.1016/j.eururo.2015.03.036

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  16 in total

Review 1.  Multidisciplinary intervention of early, lethal metastatic prostate cancer: Report from the 2015 Coffey-Holden Prostate Cancer Academy Meeting.

Authors:  Andrea K Miyahira; Joshua M Lang; Robert B Den; Isla P Garraway; Tamara L Lotan; Ashley E Ross; Tanya Stoyanova; Steve Y Cho; Jonathan W Simons; Kenneth J Pienta; Howard R Soule
Journal:  Prostate       Date:  2015-10-19       Impact factor: 4.104

2.  68Ga-PSMA PET/CT and Volumetric Morphology of PET-Positive Lymph Nodes Stratified by Tumor Differentiation of Prostate Cancer.

Authors:  Maria Vinsensia; Peter L Chyoke; Boris Hadaschik; Tim Holland-Letz; Jan Moltz; Klaus Kopka; Isabel Rauscher; Walter Mier; Markus Schwaiger; Uwe Haberkorn; Tobias Mauer; Clemens Kratochwil; Matthias Eiber; Frederik L Giesel
Journal:  J Nucl Med       Date:  2017-06-21       Impact factor: 10.057

Review 3.  Sentinel node evaluation in prostate cancer.

Authors:  Ramkishen Narayanan; Timothy G Wilson
Journal:  Clin Exp Metastasis       Date:  2018-09-05       Impact factor: 5.150

4.  Long-term oncological outcomes in patients with limited nodal disease undergoing radical prostatectomy and pelvic lymph node dissection without adjuvant treatment.

Authors:  Philipp Mandel; Clemens Rosenbaum; Raisa S Pompe; Thomas Steuber; Georg Salomon; Felix K Chun; Markus Graefen; Hartwig Huland; Derya Tilki
Journal:  World J Urol       Date:  2017-08-21       Impact factor: 4.226

Review 5.  Genomic and phenotypic heterogeneity in prostate cancer.

Authors:  Michael C Haffner; Wilbert Zwart; Martine P Roudier; Lawrence D True; William G Nelson; Jonathan I Epstein; Angelo M De Marzo; Peter S Nelson; Srinivasan Yegnasubramanian
Journal:  Nat Rev Urol       Date:  2020-12-16       Impact factor: 14.432

Review 6.  Theranostics of prostate cancer: from molecular imaging to precision molecular radiotherapy targeting the prostate specific membrane antigen.

Authors:  Harshad R Kulkarni; Aviral Singh; Thomas Langbein; Christiane Schuchardt; Dirk Mueller; Jingjing Zhang; Coline Lehmann; Richard P Baum
Journal:  Br J Radiol       Date:  2018-06-01       Impact factor: 3.039

Review 7.  The Role of Radiotherapy After Radical Prostatectomy in Patients with Prostate Cancer.

Authors:  Giorgio Gandaglia; Cesare Cozzarini; Alexandre Mottrie; Alberto Bossi; Nicola Fossati; Francesco Montorsi; Alberto Briganti
Journal:  Curr Oncol Rep       Date:  2015-12       Impact factor: 5.075

8.  Determinants of long-term survival of patients with locally advanced prostate cancer: the role of extensive pelvic lymph node dissection.

Authors:  M Moschini; N Fossati; F Abdollah; G Gandaglia; V Cucchiara; P Dell'Oglio; S Luzzago; S F Shariat; F Dehò; A Salonia; F Montorsi; A Briganti
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-11-10       Impact factor: 5.554

9.  Single Positive Lymph Node Prostate Cancer Can Be Treated Surgically without Recurrence.

Authors:  Dae Keun Kim; Kyo Chul Koo; Ali Abdel Raheem; Ki Hong Kim; Byung Ha Chung; Young Deuk Choi; Koon Ho Rha
Journal:  PLoS One       Date:  2016-03-31       Impact factor: 3.240

10.  Comparing nodal versus bony metastatic spread using tumour phylogenies.

Authors:  Stefano Mangiola; Matthew K H Hong; Marek Cmero; Natalie Kurganovs; Andrew Ryan; Anthony J Costello; Niall M Corcoran; Geoff Macintyre; Christopher M Hovens
Journal:  Sci Rep       Date:  2016-09-22       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.